Table 2.
Summary of available immunosuppressant therapies
| Baseline treatment frequency (%) | Treatment changes after COVID‐19 infection | Newly prescribed (number of reported cases) | |||
|---|---|---|---|---|---|
| Total available Cases = 325 | Not Changed** | Decreased or discontinued** | Increased** | ||
| Glucocorticoids | 204 (62.8%) | 113/145 (77.9%) | 6/145 (4.1%) | 26/145 (17.9%) | 21 |
| Antimetabolites | |||||
| Mycophenolate mofetil | 227 (69.8%) | 33/210 (15.7%) | 177/210 (84.3%) | 0/210 (0%) | 0 |
| Azathioprine or Mizoribine | 11 (3.4%) | ||||
| Calcineurin inhibitors | 289 (88.9%) | 139/256 (54.3%) | 116/256 (45.3%) | 1/256 (0.4%) | 3 |
| Immunoglobulin‐based therapies | 7 (2.1%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 41 |
| mTOR Inhibitor | 22 (6.8%) | 2/18 (11.1%) | 16/18 (88.9%) | 0/18 (0%) | 0 |
| Cept (TNF Inhibitor—Belatacept) | 6 (1.8%) | Data are only available about one discontinued case | |||
**
Number of cases with the change status/total case under the regimen as their baseline treatment (with pre‐ and post‐COVID‐19 infection available data).